{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T04:08:24Z","timestamp":1648958904861},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00108-021-01056-3","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T08:02:51Z","timestamp":1624262571000},"page":"589-596","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T-Zellen zur Behandlung von malignen B-Zell-Lymphomen"],"prefix":"10.1007","volume":"62","author":[{"given":"H.","family":"Balke-Want","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"1056_CR1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong\u00a0EA, Melenhorst\u00a0JJ, Lacey\u00a0SF et al (2017) PD\u20111 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129:1039\u20131041. https:\/\/doi.org\/10.1182\/blood-2016-09-738245","journal-title":"Blood"},{"key":"1056_CR2","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump\u00a0M, Kuruvilla\u00a0J, Couban\u00a0S et al (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J\u00a0Clin Oncol 32:3490\u20133496. https:\/\/doi.org\/10.1200\/JCO.2013.53.9593","journal-title":"J Clin Oncol"},{"key":"1056_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump\u00a0M, Neelapu\u00a0SS, Farooq\u00a0U et al (2017) Outcomes in refractory diffuse large B\u2011cell lymphoma: results from the international SCHOLAR-1\u00a0study. Blood 130:1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"1056_CR4","doi-asserted-by":"publisher","first-page":"TPS7566","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7566","volume":"37","author":"I Flinn","year":"2019","unstructured":"Flinn\u00a0I, Marris\u00a0M, Wierda\u00a0WG et al (2019) ZUMA-8: A phase 1\/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). J\u00a0Clin Oncol 37:TPS7566\u2013TPS7566. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS7566","journal-title":"J Clin Oncol"},{"key":"1056_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-138983","volume":"136","author":"NH Fowler","year":"2020","unstructured":"Fowler\u00a0NH, Dickinson\u00a0M, Dreyling\u00a0M et\u00a0al (2020) Efficacy and safety of tisagenlecleucel in adult patients with relapsed\/refractory follicular lymphoma: interim analysis of the phase 2 Elara trial. Blood 136:1\u20133. https:\/\/doi.org\/10.1182\/blood-2020-138983","journal-title":"Blood"},{"key":"1056_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta\u00a0JA, Beckwith\u00a0KA, Patel\u00a0PR et al (2016) Ibrutinib enhances chimeric antigen receptor T\u2011cell engraftment and efficacy in leukemia. Blood 127:1117\u20131127. https:\/\/doi.org\/10.1182\/blood-2015-11-679134","journal-title":"Blood"},{"key":"1056_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta\u00a0JA, Lacey\u00a0SF, Orlando\u00a0EJ et\u00a0al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563\u2013571. https:\/\/doi.org\/10.1038\/s41591-018-0010-1","journal-title":"Nat Med"},{"key":"1056_CR8","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht\u00a0C, Glass\u00a0B, Mounier\u00a0N et al (2010) Salvage regimens with autologous transplantation for relapsed large B\u2011cell lymphoma in the rituximab era. J\u00a0Clin Oncol 28:4184\u20134190. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618","journal-title":"J Clin Oncol"},{"key":"1056_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh\u00a0M, Dobrin\u00a0A, Cabriolu\u00a0A et\u00a0al (2019) CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568:112\u2013116. https:\/\/doi.org\/10.1038\/s41586-019-1054-1","journal-title":"Nature"},{"key":"1056_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","volume":"35","author":"GW Van Imhoff","year":"2017","unstructured":"Van Imhoff\u00a0GW, McMillan\u00a0A, Matasar\u00a0MJ et al (2017) Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B\u2011cell lymphoma: the ORCHARRD study. J\u00a0Clin Oncol 35:544\u2013551. https:\/\/doi.org\/10.1200\/JCO.2016.69.0198","journal-title":"J Clin Oncol"},{"key":"1056_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-136834","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson\u00a0C, Chavez\u00a0JC, Sehgal\u00a0AR et al (2020) Primary analysis of zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (iNHL). Blood 136:40\u201341. https:\/\/doi.org\/10.1182\/blood-2020-136834","journal-title":"Blood"},{"key":"1056_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-134362","volume":"136","author":"C Jacobson","year":"2020","unstructured":"Jacobson\u00a0C, Locke\u00a0FL, Ghobadi\u00a0A et al (2020) Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel). Blood 136:40\u201342. https:\/\/doi.org\/10.1182\/blood-2020-134362","journal-title":"Blood"},{"key":"1056_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2019-130983","volume":"134","author":"S Jaglowski","year":"2019","unstructured":"Jaglowski\u00a0S, Hu\u00a0Z\u2011H, Zhang\u00a0Y et al (2019) Tisagenlecleucel chimeric antigen receptor (CAR) T\u2011cell therapy for adults with diffuse large B\u2011cell lymphoma (DLBCL): real world experience from the center for international blood & marrow transplant research (CIBMTR) cellular therapy (CT) registry. Blood 134:766. https:\/\/doi.org\/10.1182\/blood-2019-130983","journal-title":"Blood"},{"key":"1056_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee\u00a0DW, Gardner\u00a0R, Porter\u00a0DL et\u00a0al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"1056_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7","author":"FL Locke","year":"2018","unstructured":"Locke\u00a0FL, Ghobadi\u00a0A, Jacobson\u00a0CA, Miklos\u00a0DB, Lekakis\u00a0LJ, Oluwole\u00a0OO, Lin\u00a0Y, Braunschweig\u00a0I, Hill\u00a0BT, Timmermann\u00a0JM, Deol\u00a0A (2018) Long-term safety and efficacy of axicabtagene ciloleucel (anti-CD19 CAR T) in refractory large B\u2011cell lymphoma: a multicenter, single arm, phase 1\u20112 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"1056_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long\u00a0AH, Haso\u00a0WM, Shern\u00a0JF et al (2015) 4\u20111BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581\u2013590. https:\/\/doi.org\/10.1038\/nm.3838","journal-title":"Nat Med"},{"key":"1056_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn\u00a0RC, Weber\u00a0EW, Sotillo\u00a0E et al (2019) c\u2011Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576:293\u2013300. https:\/\/doi.org\/10.1038\/s41586-019-1805-z","journal-title":"Nature"},{"key":"1056_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner\u00a0RG, Mackall\u00a0CL (2018) Tumor antigen escape from car t\u2011cell therapy. Cancer Discov 8:1219\u20131226. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442","journal-title":"Cancer Discov"},{"key":"1056_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner\u00a0RG, Rietberg\u00a0SP, Sotillo\u00a0E et al (2020) Tuning the antigen density requirement for CAR T\u2011cell activity. Cancer Discov 10:702\u2013723. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0945","journal-title":"Cancer Discov"},{"key":"1056_CR20","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","volume":"98","author":"N Mounier","year":"2013","unstructured":"Mounier\u00a0N, El Gnaoui\u00a0T, Tilly\u00a0H et al (2013) Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B\u2011cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study Association trial. Haematologica 98:1726\u20131731. https:\/\/doi.org\/10.3324\/haematol.2013.090597","journal-title":"Haematologica"},{"key":"1056_CR21","unstructured":"NCT03570892 (2018) Tisagenlecleucel in Adult Patients With Aggressive B\u2011cell Non-Hodgkin Lymphoma (BELINDA). https:\/\/ClinicalTrials.gov\/show\/NCT03570892"},{"key":"1056_CR22","unstructured":"NCT03575351 (2018) A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B\u2011cell Non-Hodgkin Lymphomas. https:\/\/ClinicalTrials.gov\/show\/NCT03575351"},{"key":"1056_CR23","unstructured":"NCT03870945 (2019) MB-CART2019.1 Lymphoma. https:\/\/clinicaltrials.gov\/show\/NCT03870945"},{"key":"1056_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","author":"SS Neelapu","year":"2017","unstructured":"Neelapu\u00a0SS, Locke\u00a0FL, Bartlett\u00a0NL et al (2017) Axicabtagene ciloleucel CAR T\u2011cell therapy in refractory large B\u2011cell lymphoma. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"1056_CR25","doi-asserted-by":"publisher","first-page":"TPS7585","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7585","volume":"36","author":"OO Oluwole","year":"2018","unstructured":"Oluwole\u00a0OO, Bishop\u00a0MR, Gisselbrecht\u00a0C et al (2018) ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed\/refractory diffuse large B cell lymphoma (R\/R DLBCL). J\u00a0Clin Oncol 36:TPS7585\u2013TPS7585. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.TPS7585","journal-title":"J Clin Oncol"},{"key":"1056_CR26","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando\u00a0EJ, Han\u00a0X, Tribouley\u00a0C et\u00a0al (2018) Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 24:1504\u20131506. https:\/\/doi.org\/10.1038\/s41591-018-0146-z","journal-title":"Nat Med"},{"key":"1056_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","volume":"13","author":"R Pettengell","year":"2012","unstructured":"Pettengell\u00a0R, Coiffier\u00a0B, Narayanan\u00a0G et al (2012) Pixantrone dimaleate versus other chemotherapeutic agents as a\u00a0single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: A phase 3, multicentre, open-label, randomised trial. Lancet Oncol 13:696\u2013706. https:\/\/doi.org\/10.1016\/S1470-2045(12)70212-7","journal-title":"Lancet Oncol"},{"key":"1056_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh\u00a0M, Kuhnt\u00a0E, Tr\u00fcmper\u00a0L et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6\u2011year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013\u20131022. https:\/\/doi.org\/10.1016\/S1470-2045(11)70235-2","journal-title":"Lancet Oncol"},{"key":"1056_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh\u00a0M, Schubert\u00a0J, Ziepert\u00a0M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B\u2011cell lymphomas: a\u00a0randomised controlled trial (RICOVER-60). Lancet Oncol 9:105\u2013116. https:\/\/doi.org\/10.1016\/S1470-2045(08)70002-0","journal-title":"Lancet Oncol"},{"key":"1056_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scisignal.aay8248","volume":"13","author":"BI Philipson","year":"2020","unstructured":"Philipson\u00a0BI, O\u2019Connor\u00a0RS, May\u00a0MJ et al (2020) 4\u20111BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci Signal 13:1\u201314. https:\/\/doi.org\/10.1126\/scisignal.aay8248","journal-title":"Sci Signal"},{"issue":"1","key":"1056_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, Weng Y, Grupp SA (2018) Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 11(1):35. https:\/\/doi.org\/10.1186\/s13045-018-0571-y","journal-title":"J Hematol Oncol"},{"key":"1056_CR32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter\u00a0DL, Levine\u00a0BL, Kalos\u00a0M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. TL \u2013 365. N\u00a0Engl J Med 365:725\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa1103849","journal-title":"N Engl J Med"},{"key":"1056_CR33","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz\u00a0N, Nickelsen\u00a0M, Ziepert\u00a0M et al (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B\u2011cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13:1250\u20131259. https:\/\/doi.org\/10.1016\/S1470-2045(12)70481-3","journal-title":"Lancet Oncol"},{"key":"1056_CR34","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood-2019-129411","volume":"134","author":"LM Schultz","year":"2019","unstructured":"Schultz\u00a0LM, Muffly\u00a0LS, Spiegel\u00a0JY et\u00a0al (2019) Phase I trial using CD19\/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL). Blood 134:744. https:\/\/doi.org\/10.1182\/blood-2019-129411","journal-title":"Blood"},{"key":"1056_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","author":"SJ Schuster","year":"2018","unstructured":"Schuster\u00a0SJ, Bishop\u00a0MR, Tam\u00a0CS et al (2018) Tisagenlecleucel in adult relapsed or refractory diffuse large B\u2011cell lymphoma. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"1056_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bbmt.2018.12.089","volume":"25","author":"SJ Schuster","year":"2019","unstructured":"Schuster\u00a0SJ, Bishop\u00a0MR, Tam\u00a0CS et al (2019) Long-term follow-up of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B\u2011cell lymphoma: updated analysis of Juliet study. Biol Blood Marrow Transplant 25:20\u2013S21. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.089","journal-title":"Biol Blood Marrow Transplant"},{"key":"1056_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn\u00a0LH, Herrera\u00a0AF, Flowers\u00a0CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B\u2011cell lymphoma. J\u00a0Clin Oncol 38:155\u2013165. https:\/\/doi.org\/10.1200\/JCO.19.00172","journal-title":"J Clin Oncol"},{"key":"1056_CR38","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah\u00a0NN, Johnson\u00a0BD, Schneider\u00a0D et al (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a\u00a0phase 1 dose escalation and expansion trial. Nat Med 26:1569\u20131575. https:\/\/doi.org\/10.1038\/s41591-020-1081-3","journal-title":"Nat Med"},{"key":"1056_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-140491","volume":"136","author":"T Siddiqi","year":"2020","unstructured":"Siddiqi\u00a0T, Soumerai\u00a0JD, Dorritie\u00a0KA et al (2020) Updated follow-up of patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including high-risk and Ibrutinib-treated patients. Blood 136:40\u201341. https:\/\/doi.org\/10.1182\/blood-2020-140491","journal-title":"Blood"},{"key":"1056_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh\u00a0N, Lee\u00a0YG, Shestova\u00a0O et al (2020) Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T\u2011cell dysfunction. Cancer Discov 10:552\u2013567. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0813","journal-title":"Cancer Discov"},{"key":"1056_CR41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo\u00a0E, Barrett\u00a0DM, Black\u00a0KL et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282\u20131295. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1020","journal-title":"Cancer Discov"},{"key":"1056_CR42","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow\u00a0SH, Campo\u00a0E, Pileri\u00a0SA et\u00a0al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"Suppl\u00a01","key":"1056_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2020-137045","volume":"136","author":"U Jaeger","year":"2020","unstructured":"Jaeger U, Bishop MR, Salles G, Schuster SJ, Maziarz RT, Xia H, Savchenko A, Roscoe N, Orlando E, Knoblock D, Tiwari R, Bubuteishvili Pacaud L, Corradini P (2020) Myc expression and tumor-infiltrating T cells are associated with response in patients (pts) with relapsed\/refractory diffuse large B\u2011cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the Juliet trial. Blood 136(Suppl\u00a01):48\u201349. https:\/\/doi.org\/10.1182\/blood-2020-137045","journal-title":"Blood"},{"key":"1056_CR44","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/nejmoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang\u00a0M, Munoz\u00a0J, Goy\u00a0A et al (2020) KTE-X19 CAR T\u2011cell therapy in relapsed or refractory mantle-cell lymphoma. N\u00a0Engl J Med 382:1331\u20131342. https:\/\/doi.org\/10.1056\/nejmoa1914347","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01056-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01056-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T08:03:42Z","timestamp":1624262622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01056-3"}},"subtitle":["Ein neues Therapieprinzip"],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1056"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01056-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"3 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Borchmann ist Consultant f\u00fcr Takeda, BMS, Roche, Amgen, Novartis, Celgene, Miltenyi Biotec und Gilead. Er erh\u00e4lt Forschungsunterst\u00fctzung und Hornorare von Novartis, Takeda und MSD sowie Honorare von BMS, Roche, Celgene, Miltenyi Biotec, Gilead und AbbVie. H.\u00a0Balke-Want gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}